Taniborbactam: Difference between revisions

Browse history interactively Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 21:10, 24 December 2024 editInnerstream (talk \| contribs)Autopatrolled, Extended confirmed users3,981 edits new pageTag: nowiki added		Revision as of 21:10, 24 December 2024 edit undoCitation bot (talk \| contribs)Bots5,406,912 edits Add: pmc, pmid, pages, issue, volume, journal, date, title, authors 1-17. \| Use this bot. Report bugs. \| Suggested by Innerstream \| #UCB_toolbarNext edit →
Line 59:		Line 59:
	}}		}}

	'''Taniborbactam''' (development code '''VNRX-5133''') is a pharmaceutical drug that acts as a ].<ref>{{cite journal \| doi = 10.1021/acs.jmedchem.9b01518 }}</ref> It inhibits the function of bacterial ]s which impart resistance to ]s. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the ] group which are the most frequently identified sources of acquired antibiotic resistance worldwide.<ref>{{cite journal \| doi = 10.1016/S1473-3099(23)00069-5 }}</ref>		'''Taniborbactam''' (development code '''VNRX-5133''') is a pharmaceutical drug that acts as a ].<ref>{{cite journal \| doi = 10.1021/acs.jmedchem.9b01518 \| title = Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections \| date = 2020 \| last1 = Liu \| first1 = Bin \| last2 = Trout \| first2 = Robert E. Lee \| last3 = Chu \| first3 = Guo-Hua \| last4 = McGarry \| first4 = Daniel \| last5 = Jackson \| first5 = Randy W. \| last6 = Hamrick \| first6 = Jodie C. \| last7 = Daigle \| first7 = Denis M. \| last8 = Cusick \| first8 = Susan M. \| last9 = Pozzi \| first9 = Cecilia \| last10 = De Luca \| first10 = Filomena \| last11 = Benvenuti \| first11 = Manuela \| last12 = Mangani \| first12 = Stefano \| last13 = Docquier \| first13 = Jean-Denis \| last14 = Weiss \| first14 = William J. \| last15 = Pevear \| first15 = Daniel C. \| last16 = Xerri \| first16 = Luigi \| last17 = Burns \| first17 = Christopher J. \| journal = Journal of Medicinal Chemistry \| volume = 63 \| issue = 6 \| pages = 2789–2801 \| pmid = 31765155 \| pmc = 7104248 }}</ref> It inhibits the function of bacterial ]s which impart resistance to ]s. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the ] group which are the most frequently identified sources of acquired antibiotic resistance worldwide.<ref>{{cite journal \| doi = 10.1016/S1473-3099(23)00069-5 \| title = NDM-9 resistance to taniborbactam \| date = 2023 \| last1 = Le Terrier \| first1 = Christophe \| last2 = Gruenig \| first2 = Virginia \| last3 = Fournier \| first3 = Claudine \| last4 = Nordmann \| first4 = Patrice \| last5 = Poirel \| first5 = Laurent \| journal = The Lancet Infectious Diseases \| volume = 23 \| issue = 4 \| pages = 401–402 \| pmid = 36796395 }}</ref>

	Taniborbactam, in combination with ], is in clinical trials for the treatment of bacterial infections, including ] and ].<ref>{{cite journal \| doi = 10.1056/NEJMoa2304748 }}</ref><ref>{{cite web \| url = https://adisinsight.springer.com/drugs/800049949 \| title = Cefepime/taniborbactam - VenatoRx Pharmaceuticals \| publisher = AdisInsight }}</ref>		Taniborbactam, in combination with ], is in clinical trials for the treatment of bacterial infections, including ] and ].<ref>{{cite journal \| doi = 10.1056/NEJMoa2304748 \| title = Cefepime–Taniborbactam in Complicated Urinary Tract Infection \| date = 2024 \| last1 = Wagenlehner \| first1 = Florian M. \| last2 = Gasink \| first2 = Leanne B. \| last3 = McGovern \| first3 = Paul C. \| last4 = Moeck \| first4 = Greg \| last5 = McLeroth \| first5 = Patrick \| last6 = Dorr \| first6 = Marybeth \| last7 = Dane \| first7 = Aaron \| last8 = Henkel \| first8 = Tim \| author9 = CERTAIN-1 Study Team \| journal = New England Journal of Medicine \| volume = 390 \| issue = 7 \| pages = 611–622 \| pmid = 38354140 }}</ref><ref>{{cite web \| url = https://adisinsight.springer.com/drugs/800049949 \| title = Cefepime/taniborbactam - VenatoRx Pharmaceuticals \| publisher = AdisInsight }}</ref>

	==References==		==References==

Revision as of 21:10, 24 December 2024

Pharmaceutical compound

Taniborbactam
Clinical data

Other names	VNRX-5133, VNRX5133
Legal status
Legal status	Investigational
Identifiers
IUPAC name (3R)-3-acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
CAS Number	1613267-49-4
PubChem CID	76902493
UNII	8IGQ156Z07
Chemical and physical data
Formula	C₁₉H₂₈BN₃O₅
Molar mass	389.26 g·mol
3D model (JSmol)	Interactive image
SMILES B1((CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O

Taniborbactam (development code VNRX-5133) is a pharmaceutical drug that acts as a β-lactamase inhibitor. It inhibits the function of bacterial β-lactamases which impart resistance to β-lactam antibiotics. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the New Delhi metallo-beta-lactamase 1 group which are the most frequently identified sources of acquired antibiotic resistance worldwide.

Taniborbactam, in combination with cefepime, is in clinical trials for the treatment of bacterial infections, including urinary tract infection and pyelonephritis.

References

Liu, Bin; Trout, Robert E. Lee; Chu, Guo-Hua; McGarry, Daniel; Jackson, Randy W.; Hamrick, Jodie C.; Daigle, Denis M.; Cusick, Susan M.; Pozzi, Cecilia; De Luca, Filomena; Benvenuti, Manuela; Mangani, Stefano; Docquier, Jean-Denis; Weiss, William J.; Pevear, Daniel C.; Xerri, Luigi; Burns, Christopher J. (2020). "Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections". Journal of Medicinal Chemistry. 63 (6): 2789–2801. doi:10.1021/acs.jmedchem.9b01518. PMC 7104248. PMID 31765155.
Le Terrier, Christophe; Gruenig, Virginia; Fournier, Claudine; Nordmann, Patrice; Poirel, Laurent (2023). "NDM-9 resistance to taniborbactam". The Lancet Infectious Diseases. 23 (4): 401–402. doi:10.1016/S1473-3099(23)00069-5. PMID 36796395.
Wagenlehner, Florian M.; Gasink, Leanne B.; McGovern, Paul C.; Moeck, Greg; McLeroth, Patrick; Dorr, Marybeth; Dane, Aaron; Henkel, Tim; CERTAIN-1 Study Team (2024). "Cefepime–Taniborbactam in Complicated Urinary Tract Infection". New England Journal of Medicine. 390 (7): 611–622. doi:10.1056/NEJMoa2304748. PMID 38354140.{{cite journal}}: CS1 maint: numeric names: authors list (link)
"Cefepime/taniborbactam - VenatoRx Pharmaceuticals". AdisInsight.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: